- EN
New EMCDDA products and services
New thematic paper on indicated prevention
The EMCDDA published its latest online thematic paper in February entitled: Preventing later substance use disorders in at-risk children and adolescents: a review of the theory and evidence base of indicated prevention. The study adds to the current knowledge and understanding of risk factors in the development of later drug problems, focusing on the mental health and behavioural problems that develop during childhood. The study also identifies models of best practice for prevention activities targeting vulnerable children in European countries.
Indicated prevention is a relatively new branch of drug prevention and describes a preventive approach targeting individuals at high risk of developing substance abuse or dependence later in life. Drawing on the current scientific literature, the study describes the results of research into psychosocial and individual risk and protective factors. The neurobiology of drug use and how childhood psychiatric disorders can predispose to addiction are described in detail. One chapter of the report is devoted to the ethical issues raised by indicated prevention. The report also contains a wealth of practical information. This includes guidelines for the assessment and treatment of specific psychiatric risk conditions for adolescent substance abuse, and detailed information on the indicated prevention programmes that have been identified in the study.
Downloadable in English from www.emcdda.europa.eu/publications/thematic-papers/indicated-prevention
BZP added to online ‘drug profiles’
The EMCDDA released in February the latest in its series of online drug profiles. The new profile is of the stimulant drug 1-benzylpiperazine (BZP) which was subjected to control measures and criminal provisions in EU Member States in March 2008 (countries have until March this year to take the necessary measures in line with their national laws). Completing the BZP package is a Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances.
Drug profiles, in German, English and French at www.emcdda.europa.eu/publications/drug-profiles
EMCDDA risk assessments, in English at www.emcdda.europa.eu/publications/risk-assessments
In this issue...
- In aqua veritas? Illicit drugs in wastewater
- New EU drugs action plan: mobilising European citizens
- HIV among IDUs in Europe: increasing trends in the East
- EU-LAC cities collaborate on drug treatment data collection
- Improving access to treatment
- Concerns expressed over Spice
- Towards the better treatment of addiction
- Best practice portal: selective prevention
- Drug use, a growing challenge for EU road safety
- Creating and consolidating national drug observatories
- Identifying Europe’s information needs
- Legal responses to new psychoactive substances in Europe
- Reitox Academy for the Andean Community
- National reporting: new guidelines for 2009
- Scientific Committee members present vision for next three years
- Management Board adopts 2009 work programme and budget
- Farewell to Pompidou Group chief
Drugnet Europe is also available in downloadable PDF format, for printing or offline browsing.
Drugnet Europe is the EMCDDA's newsletter launched in September 1996. The newsletter provides regular and succint information on the Centre's projects and activities to a broad readership.
Page last updated: Friday, 20 February 2009